Novel aspects of accumulation dynamics and Aβ composition in transgenic models of AD

Neurobiology of Aging

Volumn 25, Issue 9, 2004, Pages 1175-1185

  Lewis, Huw D ^a   Beher, Dirk ^a   Smith, David ^a   Hewson, Louise ^a   Cookson, Natalie ^b   Reynolds, David S ^a   Dawson, Gerard R ^a   Jiang, Michael ^c   Van Der Ploeg, Lex H T ^c   Qian, Su ^c   Rosahl, Thomas W ^a   Kalaria, Raj N ^b   Shearman, Mark S ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^b NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

amyloid; amyloid precursor protein; amyloid precursor protein containing the Swedish mutation; APP; APPswe; A ; AD; Alzheimer's disease; FAD; familial Alzheimer's disease; GFAP; glial fibrillary acidic protein

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; PRESENILIN 1;

AGING; ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE MUTATION; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TEMPORAL CORTEX; TIME OF FLIGHT MASS SPECTROMETRY; TRANSGENE;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FLUORESCENCE POLARIZATION IMMUNOASSAY; GLIOSIS; HUMANS; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; MUTATION; PEPTIDE FRAGMENTS; PRESENILIN-1; SENILE PLAQUES; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 4143106673     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2003.12.009     Document Type: Article

References (37)

1. Beher D., Elle C., Underwood J., Davis J.B., Ward R., Karran E., et al. Proteolytic fragments of Alzheimer's disease-associated presenilin 1 are present in synaptic organelles and growth cone membranes of rat brain. J. Neurochem. 72(4):1999;1564-1573
2. Beher D., Wrigley J.D., Owens A.P., Shearman M.S. Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity. J. Neurochem. 82(3):2002;563-575
3. Borchelt D.R., Ratovitski T., van Lare J., Lee M.K., Gonzales V., Jenkins N.A., et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron. 19(4):1997;939-945
4. Borchelt D.R., Thinakaran G., Eckman C.B., Lee M.K., Davenport F., Ratovitsky T., et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron. 17(5):1996;1005-1013
5. Callahan M.J., Lipinski W.J., Bian F., Durham R.A., Pack A., Walker L.C. Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. Am. J. Pathol. 158(3):2001;1173-1177
6. Chishti M.A., Yang D.S., Janus C., Phinney A.L., Horne P., Pearson J., et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 276(24):2001;21562-21570
7. Christie R.H., Bacskai B.J., Zipfel W.R., Williams R.M., Kajdasz S.T., Webb W.W., et al. Growth arrest of individual senile plaques in a model of Alzheimer's disease observed by in vivo multiphoton microscopy. J. Neurosci. 21(3):2001;858-864
8. Citron M., Westaway D., Xia W., Carlson G., Diehl T., Levesque G., et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat. Med. 3(1):1997;67-72
9. Clarke E.E., Shearman M.S. Quantitation of amyloid-beta peptides in biological milieu using a novel homogeneous time-resolved fluorescence (HTRF) assay. J. Neurosci. Methods. 102(1):2000;61-68
10. Culvenor J.G., Evin G., Cooney M.A., Wardan H., Sharples R.A., Maher F., et al. Presenilin 2 expression in neuronal cells: induction during differentiation of embryonic carcinoma cells. Exp. Cell Res. 255(2):2000;192-206
11. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Perez-tur J., et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 383(6602):1996;710-713
12. Fitzjohn S.M., Morton R.A., Kuenzi F., Rosahl T.W., Shearman M., Lewis H., et al. Age-related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that overexpress the human APP695SWE mutant form of amyloid precursor protein. J. Neurosci. 21(13):2001;4691-4698
13. Greenberg B.D., Savage M.J., Howland D.S., Ali S.M., Siedlak S.L., Perry G., et al. APP transgenesis: approaches toward the development of animal models for Alzheimer disease neuropathology. Neurobiol. Aging. 17(2):1996;153-171
14. Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12(10):1991;383-388
15. Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4(1):1998;97-100
16. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 274(5284):1996;99-102
17. Ida N., Hartmann T., Pantel J., Schroder J., Zerfass R., Forstl H., et al. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J. Biol. Chem. 271(37):1996;22908-22914
18. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron. 13(1):1994;45-53
19. Jarrett J.T., Berger E.P., Lansbury P.T. Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 32(18):1993;4693-4697
20. Johnson-Wood K., Lee M., Motter R., Hu K., Gordon G., Barbour R., et al. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 94(4):1997;1550-1555
21. Kalback W., Watson M.D., Kokjohn T.A., Kuo Y.M., Weiss N., Luehrs D.C., et al. APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry. 41(3):2002;922-928
22. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21(2):2001;372-381
23. Kim K.S., Miller D.L., Sapienza V.J., Chen C.M.J., Bai C., Grundke-Iqbal I., et al. Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. Neurosci. Res. Commun. 2:1998;121-130
24. Kuo Y.M., Emmerling M.R., Lampert H.C., Hempelman S.R., Kokjohn T.A., Woods A.S., et al. High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease. Biochem. Biophys. Res. Commun. 257(3):1999;787-791
25. Kuo Y.M., Kokjohn T.A., Beach T.G., Sue L.I., Brune D., Lopez J.C., et al. Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J. Biol. Chem. 276(16):2001;12991-12998
26. Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003;40(6):1087-93.
27. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 293(5534):2001;1487-1491
28. McGowan E., Sanders S., Iwatsubo T., Takeuchi A., Saido T., Zehr C., et al. Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol. Dis. 6(4):1999;231-244
29. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 39(3):2003;409-421
30. Qian S., Jiang P., Guan X.M., Singh G., Trumbauer M.E., Yu H., et al. Mutant human presenilin 1 protects presenilin 1 null mouse against embryonic lethality and elevates Abeta1-42/43 expression. Neuron. 20(3):1998;611-617
31. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2(8):1996;864-870
32. Seabrook G.R., Rosahl T.W. Transgenic animals relevant to Alzheimer's disease. Neuropharmacology. 38(1):1999;1-17
33. Sirinathsinghji D.J. Transgenic mouse models of Alzheimer's disease. Biochem. Soc. Trans. 26(3):1998;504-508
34. Thinakaran G., Borchelt D.R., Lee M.K., Slunt H.H., Spitzer L., Kim G., et al. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron. 17(1):1996;181-190
35. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 286(5440):1999;735-741
36. Wengenack T.M., Whelan S., Curran G.L., Duff K.E., Poduslo J.F. Quantitative histological analysis of amyloid deposition in Alzheimer's double transgenic mouse brain. Neuroscience. 101(4):2000;939-944
37. Zhang F., Eckman C., Younkin S., Hsiao K.K., Iadecola C. Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein. J. Neurosci. 17(20):1997;7655-7661